Philippe De La Rochere

Philippe De La Rochere

Auto-generated profile, based on publicly available information

Philippe De La Rochere

Institut Curie, PSL Research University, INSERM U932, Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Trends in Immunology
Verified
Journal Article
Closed access
PRPhilippe De La Rochere
Philippe De La Rochere
SGSilvia Guil-Luna
Silvia Guil-Luna
DDDidier Decaudin
Didier Decaudin
GAGeorges Azar
Georges Azar
SSSukhvinder S Sidhu
Sukhvinder S Sidhu
EPEliane Piaggio
Eliane Piaggio

18 January 2011 in Aging Cell
Verified
Journal Article
Open access
PDF file
KKKlaudia Kuranda
Klaudia Kuranda
JVJacques Vargaftig
Jacques Vargaftig
PRPhilippe de la Rochere
Philippe de la Rochere
CDChristine Dosquet
Christine Dosquet
DCDominique Charron
Dominique Charron
MGMichele Goodhardt
Michele Goodhardt
Adult stem cells are critical for maintaining cellular homeostasis throughout life, yet the effects of age on their regenerative capacity are poorly understood. All lymphoid and myeloid blood cell lineages are continuously generated from hematopoietic stem cells present in human bone marrow. With age, significant changes in the function and composition of mature blood cells are observed. In this study, we report that age-related changes also occur in the human hematopoietic stem cell compartment. We find that the proportion of multipotent CD34+CD38− cells increases in the bone marrow of elderly (>70 years) individuals. CD34+CD38+CD90−CD45RA+/−CD10− and CD34+CD33+ myeloid progenitors persist at the same level in the bone marrow, while the frequency of early CD34+CD38+CD90−CD45RA+CD10+ and committed CD34+CD19+ B-lymphoid progenitors decreases with age. In contrast to mice models of aging, transplantation experiments with immunodeficient NOD/SCID/IL-2Rγ null (NSG) mice showed that the frequency of NSG repopulating cells does not change significantly with age, and there is a decrease in myeloid lineage reconstitution. An age-related decrease in the capacity of CD34+ cells to generate myeloid cells was also seen in colony-forming assays in vitro. Thus, with increasing age, human hematopoietic stem/progenitor cells undergo quantitative changes as well as functional modifications.

1 March 2019 in OncoImmunology
Verified
Journal Article
Open access
EBEdith Borcoman
Edith Borcoman
PRPhilippe De La Rochere
Philippe De La Rochere
WRWilfrid Richer
Wilfrid Richer
SVSophie VACHER
Sophie VACHER
WCWalid Chemlali
Walid Chemlali
EPEliane Piaggio
Eliane Piaggio
Although immune checkpoint inhibitors have shown improvement in survival in comparison to chemotherapy in urothelial bladder cancer, many patients still fail to respond to these treatments and actual efforts are made to identify predictive factors of response to immunotherapy. Understanding the tumor-intrinsic molecular basis, like oncogenic pathways conditioning the presence or absence of tumor-infiltrating T cells (TILs), should provide a new rationale for improved anti-tumor immune therapies. In this study, we found that urothelial bladder cancer from human samples bearing PIK3CA gene mutations was significantly associated with lower expression of a defined immune gene signature, compared to unmutated ones. We identified a reduced 10-gene immune gene signature that discriminates muscle-invasive bladder cancer (MIBC) samples according to immune infiltration and PIK3CA mutation. Using a humanized mouse model, we observed that BKM120, a pan-PI3K inhibitor, significantly inhibited the growth of a human bladder cancer cell line bearing a PIK3CA mutation, associated to increased immune cell infiltration (hCD45+). Using qRT-PCR, we also found an increase in the expression of chemokines and immune genes in PIK3CA-mutated tumors from mice treated with BKM120, reflecting an active immune infiltrate in comparison to untreated ones. Moreover, the addition of BKM120 rendered PIK3CA-mutated tumors sensitive to PD-1 blockade. Our results provide a relevant rationale for combination strategies of PI3K inhibitors with immune checkpoint inhibitors to overcome resistance to immune checkpoint inhibitors.

1 January 2014 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
CSChristine Sedlik
Christine Sedlik
JVJames Vigneron
James Vigneron
LTLea Torrieri‐Dramard
Lea Torrieri‐Dramard
FPFabien Pitoiset
Fabien Pitoiset
JDJordan Denizeau
Jordan Denizeau
BBBertrand Bellier
Bertrand Bellier
The induction of an active immune response to control or eliminate tumours is still an unfulfilled challenge. We focused on plasmid DNA vaccines using an innovative approach whereby the antigen is expressed in association with extracellular vesicles (EVs) to facilitate antigen cross‐presentation and improve induced immunity. Our two groups had independently shown previously that DNA vaccines encoding EV‐associated antigens are more efficient at inducing cytotoxic T‐cell responses than vaccines encoding the non‐EV‐associated antigen. Here, we compared our two approaches to associate the ovalbumin (OVA) antigen to EVs: (a) by fusion to the lipid‐binding domain C1C2 of MFGE8(=lactadherin), which is exposed on the surface of secreted membrane vesicles; and (b) by fusion to retroviral Gag capsid protein, which is incorporated inside membrane‐enclosed virus‐like particles. Plasmids encoding either form of modified OVA were used as DNA‐based vaccines (i.e. injected into mice to allow in vivo expression of the antigen associated to EVs). We show that both DNA vaccines induced, with similar efficiency, OVA‐specific CD8+ T cells and total IgG antibodies. By contrast, each vaccine preferentially stimulated different isotypes of immunoglobulins, and the OVA‐C1C2‐encoding vaccine favoured antigen‐specific CD4+ T lymphocyte induction as compared to the Gag‐OVA vaccine. Nevertheless, both OVA‐C1C2 and Gag‐OVA vaccines efficiently prevented in vivo outgrowth of OVA‐expressing tumours and reduced tumour progression when administered to tumour‐bearing mice, although with variable efficacies depending on the tumour models. DNA vaccines encoding EV‐associated antigens are thus promising immunotherapy tools in cancer but also potentially other diseases.

1 March 2019 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
PCPamela Caudana
Pamela Caudana
NNNicolas Gonzalo Núñez
Nicolas Gonzalo Núñez
PRPhilippe De La Rochere
Philippe De La Rochere
APAnaïs Pinto
Anaïs Pinto
JDJordan Denizeau
Jordan Denizeau
EPEliane Piaggio
Eliane Piaggio
High-dose IL2 immunotherapy can induce long-lasting cancer regression but is toxic and insufficiently efficacious. Improvements are obtained with IL2/anti-IL2 complexes (IL2Cx), which redirect IL2 action to CD8+ T and natural killer (NK) cells. Here, we evaluated the efficacy of combining IL2Cx with blockade of inhibitory immune pathways. In an autochthonous lung adenocarcinoma model, we show that the IL2Cx/anti–PD-1 combination increases CD8+ T-cell infiltration of the lung and controls tumor growth. In the B16-OVA model, which is resistant to checkpoint inhibition, combination of IL2Cx with PD-1 or CTLA-4 pathway blockade reverses that resistance. Both combinations work by reinvigorating exhausted intratumoral CD8+ T cells and by increasing the breadth of tumor-specific T-cell responses. However, only the IL2Cx/anti–CTLA-4 combination is able to rescue NK cell antitumor function by modulating intratumoral regulatory T cells. Overall, association of IL2Cx with PD-1 or CTLA-4 pathway blockade acts by different cellular mechanisms, paving the way for the rational design of combinatorial antitumor therapies.

22 April 2016 in OncoImmunology
Verified
Journal Article
Closed access
CSChristine Sedlik
Christine Sedlik
AHAdèle Heitzmann
Adèle Heitzmann
SVSophie Viel
Sophie Viel
RSRafik Ait Sarkouh
Rafik Ait Sarkouh
CBCornélie Batisse
Cornélie Batisse
EPEliane Piaggio
Eliane Piaggio
Antibody-drug conjugates (ADC), combining the specificity of tumor recognition by monoclonal antibodies (mAb) and the powerful cytotoxicity of anticancer drugs, are currently under growing interest and development. Here, we studied the potential of Chi-Tn, a mAb directed to a glyco-peptidic tumor-associated antigen, to be used as an ADC for cancer treatment. First, we demonstrated that Chi-Tn specifically targeted tumor cells in vivo. Also, using flow cytometry and deconvolution microscopy, we showed that the Chi-Tn mAb is rapidly internalized – condition necessary to ensure the delivery of conjugated cytotoxic drugs in an active form, and targeted to early and recycling endosomes. When conjugated to saporin (SAP) or to auristatin F, the Chi-Tn ADC exhibited effective cytotoxicity to Tn-positive tumor cells in vitro, which correlated with the level of tumoral Tn expression. Furthermore, the Chi-Tn mAb conjugated to auristatin F also exhibited efficient antitumor activity in vivo, validating for the first time the use of an anti-Tn antibody as an effective ADC.